Progression-free survival end points in prostate cancer: are we truly making progress

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology Pub Date : 2024-06-17 DOI:10.1038/s41585-024-00902-x

Ravi A. Madan, Edwin M. Posadas, Richard J. Lee

引用次数: 0

Abstract

Recently, several therapeutic strategies in prostate cancer have been granted regulatory approval based on progression-free survival benefits alone, which is a relative change in the therapeutic development of prostate cancer treatments. Previously, overall survival was a requirement for approvals. Whether this approach is warranted or beneficial to patients remains unclear.

查看原文本刊更多论文

前列腺癌无进展生存期终点：我们是否真正取得了进展

最近，一些前列腺癌治疗策略仅凭无进展生存期获监管部门批准，这是前列腺癌治疗发展过程中的一个相对变化。在此之前，总生存期是获得批准的必要条件。这种方法是否有必要或对患者是否有益仍不清楚。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Urology 医学-泌尿学与肾脏学

CiteScore

12.50

自引率

2.60%

发文量

123

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.

文献相关原料

公司名称	产品信息	采购帮参考价格